

the biology of
CANCER
SECOND EDITION

Robert A. Weinberg

This page intentionally left blank
to match pagination of print book

the biology of
CANCER
SECOND EDITION

This page intentionally left blank
to match pagination of print book

the biology of
CANCER
SECOND EDITION

Robert A. Weinberg

Garland Science

Vice President: Denise Schanck
Assistant Editor: Allie Bochicchio
Production Editor and Layout: EJ Publishing Services
Text Editor: Elizabeth Zayatz
Copy Editor: Richard K. Mickey
Proofreader: Sally Huish
Illustrator: Nigel Orme
Designer: Matthew McClements, Blink Studio, Ltd.
Permissions Coordinator: Becky Hainz-Baxter
Indexer: Bill Johncocks
Director of Digital Publishing: Michael Morales
Editorial Assistant: Lamia Harik

About the Author

Robert A. Weinberg is a founding member of the Whitehead Institute for Biomedical Research. He is the Daniel K. Ludwig Professor for Cancer Research and the American Cancer Society Research Professor at the Massachusetts Institute of Technology (MIT). Dr. Weinberg is an internationally recognized authority on the genetic basis of human cancer and was awarded the U.S. National Medal of Science in 1997.

Front Cover

A micrograph section of a human *in situ* ductal carcinoma with α -smooth muscle actin stained in *pink*, cytokeratins 5 and 6 in *red-orange*, and cytokeratins 8 and 18 in *green*. (Courtesy of Werner Böcker and Igor B. Buchwalow of the Institute for Hematopathology, Hamburg, Germany.)

© 2014 by Garland Science, Taylor & Francis Group, LLC

This book contains information obtained from authentic and highly regarded sources. Every effort has been made to trace copyright holders and to obtain their permission for the use of copyright material. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

All rights reserved. No part of this book covered by the copyright hereon may be reproduced or used in any format in any form or by any means—graphic, electronic, or mechanical, including photocopying, recording, taping, or information storage and retrieval systems—without permission of the publisher.

ISBNs: 978-0-8153-4219-9 (hardcover); 978-0-8153-4220-5 (softcover).

Library of Congress Cataloging-in-Publication Data

Weinberg, Robert A. (Robert Allan), 1942-
The biology of cancer. -- Second edition.
pages cm
Includes bibliographical references.
ISBN 978-0-8153-4219-9 (hardback) -- ISBN 978-0-8153-4220-5 (pbk.) 1.
Cancer--Molecular aspects. 2. Cancer--Genetic aspects. 3. Cancer cells.
I. Title.
RC268.4.W45 2014
616.99'4--dc23
2013012335

Published by Garland Science, Taylor & Francis Group, LLC,
an informa business, 711 Third Avenue, New York, NY 10017,
USA, and 3 Park Square, Milton Park, Abingdon, OX14 4RN, UK.

Printed in the United States of America

15 14 13 12 11 10 9 8 7 6 5 4 3 2 1

 **Garland Science**
Taylor & Francis Group

Visit our website at <http://www.garlandscience.com>

Dedication

I dedicate this second edition, as the first one, to my dear wife, Amy Shulman Weinberg, who endured long hours of inattention, hearing from me repeatedly the claim that the writing of this edition was almost complete, when in fact years of work lay ahead. She deserved much better! With much love.

This page intentionally left blank
to match pagination of print book

Preface

Compared with other areas of biological research, the science of molecular oncology is a recent arrival; its beginning can be traced with some precision to a milestone discovery in 1975. In that year, the laboratory of Harold Varmus and J. Michael Bishop in San Francisco, California demonstrated that normal cell genomes carry a gene—they called it a proto-oncogene—that has the potential, following alteration, to incite cancer. Before that time, we knew essentially nothing about the molecular mechanisms underlying cancer formation; since that time an abundance of information has accumulated that now reveals in outline and fine detail how normal cells become transformed into tumor cells, and how these neoplastic cells collaborate to form life-threatening tumors.

The scientific literature on cancer pathogenesis has grown explosively and today encompasses millions of research publications. So much information would seem to be a pure blessing. After all, knowing more is always better than knowing less. In truth, it represents an embarrassment of riches. By now, we seem to know too much, making it difficult to conceptualize cancer research as a single coherent body of science rather than a patchwork quilt of discoveries that bear only a vague relationship with one another.

This book is written in a far more positive frame of mind, which holds that this patchwork quilt is indeed a manifestation of a body of science that has some simple, underlying principles that unify these diverse discoveries. Cancer research is indeed a field with conceptual integrity, much like other areas of biomedical research and even sciences like physics and chemistry, and the bewildering diversity of the cancer research literature can indeed be understood through these underlying principles.

Prior to the pioneering findings of 1975, we knew almost nothing about the molecular and cellular mechanisms that create tumors. There were some intriguing clues lying around: We knew that carcinogenic agents often, but not always, operate as mutagens; this suggested that mutant genes are involved in some fashion in programming the abnormal proliferation of cancer cells. We knew that the development of cancer is often a long, protracted process. And we knew that individual cancer cells extracted from tumors behave very differently than their counterparts in normal tissues.

Now, almost four decades later, we understand how mutant genes govern the diverse traits of cancer cells and how the traits of these individual cells determine the behavior of tumors. Many of these advances can be traced to the stunning improvements in experimental tools. The techniques of genetic analysis, which were quite primitive at the beginning of this period, have advanced to the stage where we can sequence entire tumor cell genomes in several days. (This is in sharp contrast to the state of affairs in 1975, when the sequencing of oligonucleotides represented a formidable task!) Given the critical role of genotype in determining phenotype, we now understand, at least in outline, why cancer cells behave the way that they do. On the one hand, the molecular differences among individual cancers suggest hundreds of distinct types of human cancer. On the other, molecular and biochemical analyses reveal that this bewildering diversity really manifests a small number of underlying common biochemical traits and molecular processes.

Amusingly, much of this unification was preordained by decisions made 600 million years ago. Once the laws and mechanisms of organismic development were established, they governed all that followed, including the behavior of both normal and neoplastic cells. Modern cancer researchers continue to benefit from this rigid adherence to the fundamental, evolutionarily conserved rules of life. As is evident repeatedly throughout this book, much of what we understand about cancer cells, and thus about the disease of cancer, has been learned by studying the cells of worms and fruit flies and frogs. These laws and principles are invoked repeatedly to explain the complex behaviors of human tumors. By providing context and perspective, they can be used to help us understand all types of human cancer.

While these basic principles are now in clear view, critical details continue to elude us. This explains why modern cancer research is still in active ferment, and why new, fascinating discoveries are being reported every month. While they create new perspectives, they do not threaten the solidity of the enduring truths, which this book attempts to lay out. These principles were already apparent seven years ago when the first edition of this book appeared and, reassuringly, their credibility has not been undermined by all that has followed.

In part, this book has been written as a recruiting pamphlet, as new generations of researchers are needed to move cancer research forward. They are so important because the lessons about cancer's origins, laid out extensively in this book, have not yet been successfully applied to make major inroads into the prevention and cure of this disease. This represents the major frustration of contemporary cancer research: the lessons of disease causation have rarely been followed, as day follows night, by the development of definitive cures.

And yes, there are still major questions that remain murky and poorly resolved. We still do not understand how cancer cells create the metastases that are responsible for 90% of cancer-associated mortality. We understand rather little of the role of the immune system in preventing cancer development. And while we know much about the individual signaling molecules operating inside individual human cells, we lack a clear understanding of how the complex signaling circuitry formed by these molecules makes the life-and-death decisions that determine the fate of individual cells within our body. Those decisions ultimately determine whether or not one of our cells begins the journey down the long road leading to cancerous proliferation and, finally, to a life-threatening tumor.

Contemporary cancer research has enriched numerous other areas of modern biomedical research. Consequently, much of what you will learn from this book will be useful in understanding many aspects of immunology, neurobiology, developmental biology, and a dozen other biomedical research fields. Enjoy the ride!

Robert A. Weinberg
Cambridge, Massachusetts
March 2013

A Note to the Reader

The second edition of this book is organized, like the first, into 16 chapters of quite different lengths. The conceptual structure that was established in the first edition still seemed to be highly appropriate for the second, and so it was retained. What has changed are the contents of these chapters: some have changed substantially since their first appearance seven years ago, while others—largely early chapters—have changed little. The unchanging nature of the latter is actually reassuring, since these chapters deal with early conceptual foundations of current molecular oncology; it would be most unsettling if these foundational chapters had undergone radical revision, which would indicate that the earlier edition was a castle built on sand, with little that could be embraced as well-established, unchanging certainties.

The chapters are meant to be read in the order that they appear, in that each builds on the ideas that have been presented in the chapters before it. The first chapter is a condensed refresher course for undergraduate biology majors and pre-doctoral students; it lays out many of the background concepts that are assumed in the subsequent chapters.

The driving force of these two editions has been a belief that modern cancer research represents a conceptually coherent field of science that can be presented as a clear, logical progression. Embedded in these discussions is an anticipation that much of this information will one day prove useful in devising novel diagnostic and therapeutic strategies that can be deployed in oncology clinics. Some experiments are described in detail to indicate the logic supporting many of these concepts. You will find numerous schematic drawings, often coupled with micrographs, that will help you to appreciate how experimental results have been assembled, piece-by-piece, generating the syntheses that underlie molecular oncology.

Scattered about the text are “Sidebars,” which consist of commentaries that represent detours from the main thrust of the discussion. Often these Sidebars contain anecdotes or elaborate on ideas presented in the main text. Read them if you are interested, or skip over them if you find them too distracting. They are presented to provide additional interest—a bit of extra seasoning in the rich stew of ideas that constitutes contemporary research in this area. The same can be said about the “Supplementary Sidebars,” which have been relegated to the DVD-ROM that accompanies this book. These also elaborate upon topics that are laid out in the main text and are cross-referenced throughout the book. Space constraints dictated that the Supplementary Sidebars could not be included in the hardcopy version of the textbook.

Throughout the main text you will find extensive cross-references whenever topics under discussion have been introduced or described elsewhere. Many of these have been inserted in the event that you read the chapters in an order different from their presentation here. These cross-references should not provoke you to continually leaf through other chapters in order to track down cited sections or figures. If you feel that you will benefit from earlier introductions to a topic, use these cross-references; otherwise, ignore them.

Each chapter ends with a forward-looking summary entitled “Synopsis and Prospects.” This section synthesizes the main concepts of the chapter and often addresses

ideas that remain matters of contention. It also considers where research might go in the future. This overview is extended by a list of key concepts and a set of questions. Some of the questions are deliberately challenging and we hope they will provoke you to think more deeply about many of the issues and concepts developed. Finally, most chapters have an extensive list of articles from research journals. These will be useful if you wish to explore a particular topic in detail. Almost all of the cited references are review articles, and many contain detailed discussions of various subfields of research as well as recent findings. In addition, there are occasional references to older publications that will clarify how certain lines of research developed.

Perhaps the most important goal of this book is to enable you to move beyond the textbook and jump directly into the primary research literature. This explains why some of the text is directed toward teaching the elaborate, specialized vocabulary of the cancer research literature, and many of its terms are defined in the glossary. Boldface type has been used throughout to highlight key terms that you should understand. Cancer research, like most areas of contemporary biomedical research, is plagued by numerous abbreviations and acronyms that pepper the text of many published reports. The book provides a key to deciphering this alphabet soup by defining these acronyms. You will find a list of such abbreviations in the back.

Also contained in the book is a newly compiled List of Key Techniques. This list will assist you in locating techniques and experimental strategies used in contemporary cancer research.

The DVD-ROM that accompanies the book also contains a PowerPoint® presentation for each chapter, as well as a companion folder that contains individual JPEG files of the book images including figures, tables, and micrographs. In addition, you will find on this disc a variety of media for students and instructors: movies and audio recordings. There is a selection of movies that will aid in understanding some of the processes discussed; these movies are referenced on the first page of the corresponding chapter in a blue box. The movies are available in QuickTime and WMV formats, and can be used on a computer or transferred to a mobile device. The author has also recorded mini-lectures on the following topics for students and instructors: Mutations and the Origin of Cancer, Growth Factors, p53 and Apoptosis, Metastasis, Immunology and Cancer, and Cancer Therapies. These are available in MP3 format and, like the movies, are easy to transfer to other devices. These media items, as well as future media updates, are available to students and instructors at: <http://www.garlandscience.com>. On the website, qualified instructors will be able to access a newly created Question Bank. The questions are written to test various levels of understanding within each chapter. The instructor's website also offers access to instructional resources from all of the Garland Science textbooks. For access to instructor's resources please contact your Garland Science sales representative or e-mail science@garland.com.

The poster entitled "The Pathways of Human Cancer" summarizes many of the intracellular signaling pathways implicated in tumor development. This poster has been produced and updated for the Second Edition by Cell Signaling Technology.

Because this book describes an area of research in which new and exciting findings are being announced all the time, some of the details and interpretations presented here may become outdated (or, equally likely, proven to be wrong) once this book is in print. Still, the primary concepts presented here will remain, as they rest on solid foundations of experimental results.

The author and the publisher would greatly appreciate your feedback. Every effort has been made to minimize errors. Nonetheless, you may find them here and there, and it would be of great benefit if you took the trouble to communicate them. Even more importantly, much of the science described herein will require reinterpretation in coming years as new discoveries are made. Please email us at science@garland.com with your suggestions, which will be considered for incorporation into future editions.

PowerPoint is a registered trademark of the Microsoft Corporation in the United States and/or other countries.

Acknowledgments

The science described in this book is the opus of a large, highly interactive research community stretching across the globe. Its members have moved forward our understanding of cancer immeasurably over the past generation. The colleagues listed below have helped the author in countless ways, large and small, by providing sound advice, referring me to critical scientific literature, analyzing complex and occasionally contentious scientific issues, and reviewing individual chapters and providing much-appreciated critiques. Their scientific expertise and their insights into pedagogical clarity have proven to be invaluable. Their help extends and complements the help of an equally large roster of colleagues

Second edition Eric Abbate, Janis Abkowitz, Julian Adams, Peter Adams, Gemma Alderton, Lourdes Aleman, Kari Alitalo, C. David Allis, Claudia Andl, Annika Antonsson, Paula Apsell, Steven Artandi, Carlos Arteaga, Avi Ashkenazi, Duncan Baird, Amy Baldwin, Frances Balkwill, Allan Balmain, David Bartel, Josep Baselga, Stephen Baylin, Philip Beachy, Robert Beckman, Jürgen Behrens, Roderick Beijersbergen, George Bell, Robert Benezra, Thomas Benjamin, Michael Berger, Arnold Berk, René Bernards, Rameen Beroukhim, Donald Berry, Timothy Bestor, Mariann Bienz, Brian Bierie, Leon Bignold, Walter Birchmeier, Oliver Bischof, John Bixby, Jenny Black, Elizabeth Blackburn, Maria Blasco, Matthew Blatnik, Günter Blobel, Julian Blow, Bruce Boman, Gareth Bond, Katherine Borden, Lubor Borsig, Piet Borst, Blaise Bossy, Michael Botchan, Nancy Boudreau, Henry Bourne, Marina Bousquet, Thomas Brabletz, Barbara Brandhuber, Ulrich Brandt, James Brenton, Marta Briarava, Cathrin Brisken, Jacqueline Bromberg, Myles Brown, Patrick Brown, Thijn Brummelkamp, Ferdinando Bruno, Richard Bucala, Janet Butel, Eliezer Calo, Eleanor Cameron, Ian Campbell, Judith Campbell, Judith Campisi, Lewis Cantley, Yihai Cao, Mario Capecchi, Robert Carlson, Peter Carmeliet, Kermit Carraway, Oriol Casanovas, Tom Cech, Howard Cedar, Ann Chambers, Eric Chang, Mark Chao, Iain Cheeseman, Herbert Chen, Jen-Tsan Chi, Lewis Chodosh, Gerhard Christofori, Inhee Chung, Karen Cichowski, Daniela Cimini, Tim Clackson, Lena Claesson-Welsh, Michele Clamp, Trevor Clancy, Rachael Clark, Bayard Clarkson, James Cleaver, Don Cleveland, David Cobrinik, John Coffin, Philip Cohen, Robert Cohen, Michael Cole, Hilary Collier, Kathleen Collins, Duane Compton, John Condeelis, Simon Cook, Christopher

who helped with the preparation of the first edition. These individuals are representatives of a community, whose members are, virtually without exception, ready and pleased to provide a helping hand to those who request it. I am most grateful to them. Not listed below are the many colleagues who generously provided high quality versions of their published images; they are acknowledged through the literature citations in the figure legends. I would like to thank the following for their suggestions in preparing this edition, as well as those who helped with the first edition. (Those who helped on this second edition are listed immediately, while those who helped with the first edition follow.)

Counter, Sara Courtneidge, Lisa Coussens, Charles Craik, James Darnell, Mark Davis, George Daley, Titia de Lange, Pierre De Meyts, Hugues de Thé, Rik Derynck, Mark Dewhirst, James DeCaprio, Mark Depristo, Channing Der, Tom DiCesare, John Dick, Daniel DiMaio, Charles Dimitroff, Nadya Dimitrova, Charles Dinarello, Joseph DiPaolo, Peter Dirks, Vishwa Dixit, Lawrence Donehower, Philip Donoghue, Martin Dorf, David Dornan, Gian Paolo Dotto, Steven Dowdy, James Downing, Harry Drabkin, Brian Druker, Crislyn D'Souza-Schorey, Eric Duell, Patricia Duffner, Michel DuPage, Robert Duronio, Michael Dyer, Nick Dyson, Connie Eaves, Michael Eck, Mikala Egeblad, Charles Eigenbrot, Steve Elledge, Robert Eisenman, Susan Erster, Manel Esteller, Mark Ewen, Patrick Eyers, Dorian Fabbro, Reinhard Fässler, Mark Featherstone, David Felser, Karen Ferrante, Soldano Ferrone, Isaiah Fidler, Barbara Fingleton, Zvi Fishelson, Ignacio Flores, Antonio Foji, David Foster, A. Raymond Frackelton jr., Hervé Wolf Fridman, Peter Friedl, Kenji Fukasawa, Priscilla A. Furth, Vladimir Gabai, Brenda Gallie, Jerome Galon, Sanjiv Sam Gambhir, Levi Garraway, Yan Geng, Bruce Gelb, Richard Gelber, Frank Gertler, Gad Getz, Edward Giovannucci, Michael Gnant, Sumita Gokhale, Leslie Gold, Alfred Goldberg, Richard Goldsby, Jesus Gomez-Navarro, David Gordon, Eyal Gottlieb, Stephen Grant, Alexander Greenhough, Christoph Kahlert, Florian Greten, Jay Grisolano, Athur Grollman, Bernd Groner, Wenjun Guo, Piyush Gupta, Daniel Haber, William Hahn, Kevin Haigis, Marcia Haigis, William Hait, Thanos Halazonetis, John Haley, Stephen Hall, Douglas Hanahan, Steven Hanks, J. Marie Hardwick, Iswar Hariharan, Ed Harlow, Masanori Hatakeyama, Georgia Hatzivassiliou, Lin He, Matthias Hebrok, Stephen Hecht,

Kristian Helin, Samuel Hellman, Michael Hemann, Linda Hendershot, Meenhard Herlyn, Julian Heuberger, Philip Hinds, Susan Hilsenbeck, Michelle Hirsch, Andreas Hochwagen, H. Robert Horvitz, Susan Horwitz, Peter Howley, Ralph Hruban, Peggy Hsu, David Huang, Paul Huang, Robert Huber, Honor Hugo, Tony Hunter, Richard Hynes, Tan Ince, Yoko Irie, Mark Israel, Jean-Pierre Issa, Yoshiaki Ito, Michael Ittmann, Shalev Itzkovitz, Tyler Jacks, Stephen Jackson, Rudolf Jaenisch, Rakesh Jain, Katherine Janeway, Ahmedin Jemal, Harry Jenq, Kim Jensen, Josef Jiricny, Claudio Joazeiro, Bruce Johnson, Candace Johnson, David Jones, Peter Jones, Nik Joshi, Johanna Joyce, William Kaelin, Kong Jie Kah, Nada Kalaany, Raghu Kalluri, Lawrence Kane, Antoine Karnoub, John Katzenellenbogen, Khandan Keyomarsi, Katherine Janeway, William Kaelin jr., Andrius Kazlauskas, Joseph Kelleher, Elliott Kieff, Nicole King, Christian Klein, Pamela Klein, Frederick Koerner, Richard Kolesnick, Anthony Komaroff, Konstantinos Konstantopoulos, Jordan Krall, Igor Kramnik, Wilhelm Krek, Guido Kroemer, Eve Kruger, Genevieve Kruger, Madhu Kumar, Charlotte Kuperwasser, Thomas Kupper, Bruno Kyewski, Sunil Lakhani, Eric Lander, Lewis Lanier, Peter Lansdorp, David Largaespada, Michael Lawrence, Emma Lees, Jacqueline Lees, Robert Lefkowitz, Mark Lemmon, Stanley Lemon, Arnold Levine, Beth Levine, Ronald Levy, Ephrat Levy-Lahad, Kate Liddell, Stuart Linn, Marta Lipinski, Joe Lipsick, Edison Liu, David Livingston, Harvey Lodish, Lawrence Loeb, Jay Loeffler, David Louis, Julie-Aurore Losman, Scott Lowe, Haihui Lu, Kunxin Luo, Mathieu Lupien, Li Ma, Elisabeth Mack, Alexander MacKerell jr., Ben Major, Tak Mak, Shiva Malek, Scott Manalis, Sridhar Mani, Matthias Mann, Alberto Mantovani, Richard Marais, Jean-Christophe Marine, Sanford Markowitz, Ronen Marmorstein, Lawrence Marnett, Chris Marshall, G. Steven Martin, Joan Massagué, Lynn Matrisian, Massimiliano Mazzone, Sandra McAllister, Grant McArthur, David McClay, Donald McDonald, David Glenn McFadden, Wallace McKeenan, Margaret McLaughlin-Drubin, Anthony Means, René Medema, Cornelis Melief, Craig Mermel, Marek Michalak, Brian Miller, Nicholas Mitsiades, Sibylle Mittnacht, Holger Moch, Ute Moll, Deborah Morrison, Aristides Moustakis, Gregory Mundy, Cornelius Murre, Ruth Muschel, Senthil Muthuswamy, Jeffrey Myers, Harikrishna Nakshatri, Inke Näthke, Geoffrey Neale, Ben Neel, Joel Neilson, M. Angela Nieto, Irene Ng, Ingo Nindl, Larry Norton, Roel Nusse, Shuji Ogino, Kenneth Olive, Andre Oliveira, Gilbert Omenn, Tamer Onder, Moshe Oren, Barbara Osborne, Liliana Ossowski, David Page, Klaus Pantel, David Panzarella, William Pao, Jongsun Park, Paul Parren, Ramon Parsons, Dhavalkumar Patel, Mathias Pawlak, Tony Pawson, Daniel Peeper, Mark Peifer, David Pellman, Tim Perera, Charles Perou, Mary Ellen Perry, Manuel Perucho, Richard Pestell, Julian Peto, Richard Peto, Stefano Piccolo, Jackie Pierce, Eli Pikarsky, Hidde Ploegh, Nikolaus Pfanner, Kristy Pluchino, Heike Pohla, Paul Polakis, Michael

Pollak, John Potter, Carol Prives, Lajos Pusztai, Xuebin Qin, Priyamvada Rai, Terence Rabbitts, Anjana Rao, Julia Rastelli, David Raulet, John Rebers, Roger Reddel, Peter Reddien, Danny Reinberg, Michael Retsky, Jeremy Rich, Andrea Richardson, Tim Richmond, Gail Risbridger, Paul Robbins, James Roberts, Leonardo Rodriguez, Veronica Rodriguez, Mark Rolfe, Michael Rosenblatt, David Rosenthal, Theodora Ross, Yolanda Roth, David Rowitch, Brigitte Royer-Pokora, Anil Rustgi, David Sabatini, Erik Sahai, Jesse Salk, Leona Samson, Yarden Samuels, Bengt Samuelsson, Christopher Sansam, Richard Santen, Van Savage, Andrew Sharrocks, Brian Schaffhausen, Pepper Schedin, Christina Scheel, Rachel Schiff, Joseph Schlessinger, Ulrich Schopfer, Hubert Schorle, Deborah Schrag, Brenda Schulman, Wolfgang Schulz, Bert Schutte, Hans Schreiber, Robert Schreiber, Martin Schwartz, Ralph Scully, John Sedivy, Helmut Seitz, Manuel Serrano, Jeffrey Settleman, Kevin Shannon, Phillip Sharp, Norman Sharpless, Jerry Shay, Stephen Sherwin, Yigong Shi, Tsukasa Shibuya, Ben-Zion Shilo, Piotr Sicinski, Daniel Silver, Arun Singh, Michail Sitkovsky, George Sledge, Jr., Mark Sliwkowski, David I. Smith, Eric Snyder, Pierre Sonveaux, Jean-Charles Soria, Ben Stanger, Sheila Stewart, Charles Stiles, Jayne Stommel, Shannon Stott, Jenny Stow, Michael Stratton, Ravid Straussman, Jonathan Strosberg, Charles Streuli, Herman Suit, Peter Sun, Thomas Sutter, Kathy Svoboda, Alejandro Sweet-Cordero, Mario Sznol, Clifford Tabin, Wai Leong Tam, Hsin-Hsiung Tai, Makoto Taketo, Wai Leong Tam, Filemon Tan, Michael Tangrea, Masae Tatematsu, Steven Teitelbaum, Sabine Tejpar, Adam Telerman, Jennifer Temel, David Tenenbaum, Mine Tezal, Jean Paul Thiery, Craig Thompson, Michael Thun, Thea Tlsty, Rune Toftgård, Nicholas Tonks, James Trager, Donald L. Trump, Scott Valastyan, Linda van Aelst, Benoit van den Eynde, Matthew Vander Heiden, Maarten van Lohuizen, Eugene van Scott, Peter Vaupel, Laura van't Veer, George Vassiliou, Inder Verma, Gabriel Victora, Christoph Viebahn, Danijela Vignjevic, Bert Vogelstein, Robert Vonderheide, Daniel von Hoff, Dorien Voskuil, Karen Vousden, Geoffrey Wahl, Lynne Waldman, Herbert Waldmann, Graham Walker, Rongfu Wang, Patricia Watson, Bill Weis, Stephen Weiss, Irv Weissman, Danny Welch, H. Gilbert Welch, Zena Werb, Marius Wernig, Bengt Westermarck, John Westwick, Eileen White, Forest White, Max Wicha, Walter Willett, Catherine Wilson, Owen Witte, Alfred Wittinghofer, Norman Wolmark, Sopit Wongkham, Richard Wood, Nicholas Wright, Xu Wu, David Wynford-Thomas, Michael Yaffe, Jing Yang, James Yao, Yosef Yarden, Robert Yauch, Xin Ye, Sam Yoon, Richard Youle, Richard Young, Patrick Zarrinkar, Ann Zaubler, Jiri Zavadil, Lin Zhang, Alicia Zhou, Ulrike Ziebold, Kai Zinn, Johannes Zuber, James Zwiebel.

Special thanks to **Makoto Mark Taketo** of Kyoto University and **Richard A. Goldsby** of Amherst College.

First edition Joan Abbott, Eike-Gert Achilles, Jerry Adams, Kari Alitalo, James Allison, David Alpers, Fred Alt, Carl Anderson, Andrew Aprikyan, Jon Aster, Laura Attardi, Frank Austen, Joseph Avruch, Sunil Badve, William Baird, Frances Balkwill, Allan Balmain, Alan Barge, J. Carl Barrett, David Bartel, Renato Baserga, Richard Bates, Philip Beachy, Camille Bedrosian, Anna Belkina, Robert Benezra, Thomas Benjamin, Yinon Ben-Neriah, Ittai Ben-Porath, Bradford Berk, René Bernards, Anton Berns, Kenneth Berns, Monica Bessler, Neil Bhowmick, Marianne Bienz, Line Bjørge, Harald von Boehmer, Gareth Bond, Thierry Boon, Dorin-Bogdan Borza, Chris Boshoff, Noël Bouck, Thomas Brabletz, Douglas Brash, Cathrin Briskén, Garrett Brodeur, Patrick Brown, Richard Bucala, Patricia Buffler, Tony Burgess, Suzanne Bursaux, Randall Burt, Stephen Bustin, Janet Butel, Lisa Butterfield, Blake Cady, John Cairns, Judith Campisi, Harvey Cantor, Robert Cardiff, Peter Carroll, Arlindo Castelanho, Bruce Chabner, Ann Chambers, Howard Chang, Andrew Chess, Ann Cheung, Lynda Chin, Francis Chisari, Yunje Cho, Margaret Chou, Karen Cichowski, Michael Clarke, Hans Clevers, Brent Cochran, Robert Coffey, John Coffin, Samuel Cohen, Graham Colditz, Kathleen Collins, Dave Comb, John Condeelis, Suzanne Cory, Christopher Counter, Sara Courtneidge, Sandra Cowan-Jacob, John Crispino, John Crissman, Carlo Croce, Tim Crook, Christopher Crum, Marcia Cruz-Correa, Gerald Cunha, George Daley, Riccardo Dalla-Favera, Alan D'Andrea, Chi Dang, Douglas Daniels, James Darnell, Jr., Robert Darnell, Galina Deichman, Titia de Lange, Hugues de Thé, Chuxia Deng, Edward Dennis, Lucas Dennis, Ronald DePinho, Theodora Devereaux, Tom DiCesare, Jules Dienstag, John DiGiovanni, Peter Dirks, Ethan Dmitrovsky, Daniel Donoghue, John Doorbar, G. Paolo Dotto, William Dove, Julian Downward, Glenn Dranoff, Thaddeus Dryja, Raymond DuBois, Nick Duesbery, Michel DuPage, Harold Dvorak, Nicholas Dyson, Michael Eck, Walter Eckhart, Argiris Efstratiadis, Robert Eisenman, Klaus Elenius, Steven Elledge, Elissa Epel, John Eppig, Raymond Erikson, James Eshleman, John Essigmann, Gerard Evan, Mark Ewen, Guowei Fang, Juli Feigon, Andrew Feinberg, Stephan Feller, Bruce Fenton, Stephen Fesik, Isaiah Fidler, Gerald Fink, Alain Fischer, Zvi Fishelson, David Fisher, Richard Fisher, Richard Flavell, Riccardo Fodde, M. Judah Folkman, David Foster, Uta Francke, Emil Frei, Errol Friedberg, Peter Friedl, Stephen Friend, Jonas Frisen, Elaine Fuchs, Margaret Fuller, Yuen Kai (Teddy) Fung, Kyle Furge, Amar Gajjar, Joseph Gall, Donald Ganem, Judy Garber, Frank Gertler, Charlene Gilbert, Richard Gilbertson, Robert Gillies, Doron Ginsberg, Edward Giovannucci, Inna Gitelman, Steve Goff, Lois Gold, Alfred Goldberg, Mitchell Goldfarb, Richard Goldsby, Joseph Goldstein, Susanne Gollin, Mehra Golshan, Todd Golub, Jeffrey Gordon, Michael Gordon, Siamon Gordon, Martin Gorovsky, Arko Gorter, Joe Gray, Douglas Green, Yoram Groner, John Grooman, Steven Grossman, Wei Gu, David Guertin, Piyush Gupta, Barry Gusterson, Daniel Haber, James Haber, William Hahn, Kevin Haigis, Senitiroh Hakomori, Alan Hall, Dina Gould Halme, Douglas Hanahan, Philip Hanawalt, Adrian Harris, Curtis Harris, Lyndsay Harris, Stephen Harrison, Kimberly Hartwell, Leland Hartwell, Harald zur Hausen, Carol Heckman, Ruth Heimann, Samuel Hellman, Brian Hemmings, Lothar Hennighausen, Meenhard Herlyn, Glenn Herrick, Avram Hershko, Douglas Heuman, Richard Hodes, Jan Hoeijmakers, Robert Hoffman, Robert Hoover, David Hopwood, Gabriel Hortobagyi, H. Robert Horvitz, Marshall Horwitz, Alan Houghton, Peter Howley, Robert Huber, Tim Hunt, Tony Hunter, Stephen Hursting, Nancy Hynes, Richard Hynes, Antonio Iavarone, J. Dirk Iglehart, Tan Ince, Max Ingman, Mark Israel, Kurt Isselbacher, Tyler Jacks, Rudolf Jaenisch, Rakesh Jain, Bruce Johnson, David Jones, Richard Jones, William Kaelin, Jr., Raghu Kalluri, Alexander Kamb, Barton Kamen, Manolis Kamvysselis, Yibin Kang, Philip Kantoff, Paul Kantrowitz, Jan Karlsreder, Michael Kastan, Michael Kauffman, William Kaufmann, Robert Kerbel, Scott Kern, Khandan Keyomarsi, Marc Kirschner, Christoph Klein, George Klein, Yoel Kloog, Alfred Knudson, Frederick Koerner, Anthony Komaroff, Kenneth Korach, Alan Korman, Eva Kramarova, Jackie Kravaka, Wilhelm Krek, Charlotte Kuperwasser, James Kyranos, Carole LaBonne, Peter Laird, Sergio Lamprecht, Eric Lander, Laura Landweber, Lewis Lanier, Andrew Lassar, Robert Latek, Lester Lau, Derek Le Roith, Chung Lee, Keng Boon Lee, Richard Lee, Jacqueline Lees, Rudolf Leibel, Mark Lemmon, Christoph Lengauer, Jack Lenz, Gabriel Leung, Arnold Levine, Beth Levine, Jay Levy, Ronald Levy, Fran Lewitter, Frederick Li, Siming Li, Frank Lieberman, Elaine Lin, Joachim Lingner, Martin Lipkin, Joe Lipsick, David Livingston, Harvey Lodish, Lawrence Loeb, Edward Loechler, Michael Lotze, Lawrence Lum, Vicky Lundblad, David MacPherson, Sendurai Mani, Alberto Mantovani, Sandy Markowitz, Larry Marnett, G. Steven Martin, Seamus Martin, Joan Massagué, Patrice Mathevet, Paul Matsudaira, Andrea McClatchey, Frank McCormick, Patricia McManus, Mark McMenamin, U. Thomas Meier, Matthew Meyerson, George Miller, Nathan Miselis, Randall Moon, David Morgan, Rebecca Morris, Simon Conway Morris, Robert Moschel, Bernard Moss, Paul Mueller, Anja Mueller-Homey, William A. Muller, Gregory Mundy, Karl Münger, Lance Munn, Ruth Muschel, Lee Nadler, David G. Nathan, Jeremy Nathans, Sergei Nedospasov, Benjamin Neel, David Neuhaus, Donald Newmeyer, Leonard Norkin, Lloyd Old, Kenneth Olive, Tamer Onder, Moshe Oren, Terry Orr-Weaver, Barbara Osborne, Michele Pagano, David Page, Asit Parikh, Chris Parker, William Paul, Amanda Paulovich, Tony Pawson, Mark Peifer, David Pellman, David Phillips, Jacqueline Pierce, Malcolm Pike, John Pintar, Maricarmen Planas-Silva, Roland Pochet, Daniel Podolsky, Beatriz Pogo, Roberto Polakiewicz, Jeffrey Pollard, Nicolae Popescu, Christoph Poremba, Richmond Prehn, Carol Prives, Vito Quaranta, Peter Rabinovitch, Al Rabson, Priyamvada Rai, Klaus Rajewsky, Sridhar Ramaswamy, Anapoorni Rangarajan, Jeffrey Ravetch, Ilaria Rebay, John Reed, Steven Reed, Alan Rein, Ee Chee Ren, Elizabeth Repasky, Jeremy Rich, Andrea Richardson, Dave Richardson, Darrell Rigel, James Roberts, Diane Rodi, Clifford Rosen, Jeffrey Rosen, Neal Rosen, Naomi Rosenberg, Michael Rosenblatt, Theodora Ross, Martine Roussel, Steve Rozen, Jeffrey Ruben, José Russo, David Sabatini, Julien Sage, Ronit Sarid, Edward Sausville, Charles Sawyers, David Scadden, David Schatz, Christina Scheel, Joseph Schlessinger, Anja Schmidt, Stuart Schnitt, Robert Schoen, Robert Schreiber, Edward Scolnick, Ralph Scully, Harold

Seifried, William Sessa, Jeffrey Settleman, Fergus Shanahan, Jerry Shay, James Sherley, Charles Sherr, Ethan Shevach, Chiaho Shih, Frank Sicheri, Peter Sicinski, Sandy Simon, Dinah Singer, Arthur Skarin, Jonathan Skipper, Judy Small, Gilbert Smith, Lauren Sompayrac, Holger Sondermann, Gail Sonenshein, Deborah Spector, Michael Sporn, Eric Stanbridge, E. Richard Stanley, Louis Staudt, Philipp Steiner, Ralph Steinman, Gunther Stent, Sheila Stewart, Charles Stiles, Jonathan Stoye, Michael Stratton, Bill Sugden, Takashi Sugimura, John Sullivan, Nevin Summers, Calum Sutherland, Clifford Tabin, John Tainer, Jussi Taipale, Shinichiro Takahashi, Martin Tallman, Steven Tannenbaum, Susan Taylor, Margaret Tempero, Masaaki Terada, Satvir Tevethia, Jean Paul Thiery, William Thilly, David Thorley-Lawson, Jay Tischfield, Robertus Tollenaar, Stephen Tomlinson, Dimitrios Trichopoulos, Elaine Trujillo, James Umen, Alex van der Eb, Wim van Egmond, Diana van Heemst, Laura van't Veer, Harold Varmus, Alexander Varshavsky, Anna Velcich, Ashok Venkataraman, Björn Vennström, Inder Verma, Shelia Violette, Bert Vogelstein, Peter Vogt, Olga Volpert, Evan Vosburgh, Geoffrey Wahl, Graham Walker, Gernot Walter, Jack Wands, Elizabeth Ward, Jonathan Warner, Randolph Watnick, I. Bernard Weinstein, Robin Weiss, Irving Weissman, Danny Welch, H. Gilbert Welch, Zena Werb, Forest White, Michael White, Raymond White, Max Wicha, Walter Willet, Owen Witte, Richard Wood, Andrew Wyllie, John Wysolmerski, Michael Yaffe, Yukiko Yamashita, George Yancopoulos, Jing Yang, Moshe Yaniv, Chun-Nan Yeh, Richard Youle, Richard Young, Stuart Yuspa, Claudio Zanon, David Zaridze, Patrick Zarrinkar, Bruce Zetter, Drazen Zimonjic, Leonard Zon, Weiping Zou

Readers: Through their careful reading of the text, these graduate students provided extraordinarily useful feedback in improving many sections of this book and in clarifying sections that were, in their original versions, poorly written and confusing.

Jamie Weyandt (Duke University), Matthew Crowe (Duke University), Venice Calinisan Chiueh (University of California, Berkeley), Yvette Soignier (University of California, Berkeley)

Question Bank: Jamie Weyandt also produced the accompanying question bank available to qualified adopters on the instructor resource site.

Whitehead Institute/MIT: Christine Hickey was responsible over several years' time in helping to organize the extensive files that constituted each chapter. Her help was truly extraordinary.

Dave Richardson of the Whitehead Institute library helped on countless occasions to retrieve papers from obscure corners of the vast scientific literature, doing so with lightning speed!

Garland: While this book has a single recognized author, it really is the work of many hands. The prose was edited by Elizabeth Zayatz and Richard K. Mickey, two editors who are nothing less than superb. To the extent that this book is clear and readable, much of this is a reflection of their dedication to clarity, precision of language, graceful syntax, and the use

of images that truly serve to enlighten rather than confound. I have been most fortunate to have two such extraordinary people looking over my shoulder at every step of the writing process. And, to be sure, I have learned much from them. I cannot praise them enough!

Many of the figures are the work of Nigel Orme, an illustrator of great talent, whose sense of design and dedication to precision and detail are, once again, nothing less than extraordinary.

Garland Science determined the structure and design and provided unfaltering support and encouragement through every step of the process that was required to bring this project to fruition. Denise Schanck gave guidance and cheered me on every step of the way. Unfailingly gracious, she is, in every sense, a superb publisher, whose instincts for design and standards of quality publishing are a model. All textbook authors should be as fortunate as I have been to have someone of her qualities at the helm!

The editorial and logistical support required to organize and assemble a book of this complexity was provided first by Janete Scobie and then over a longer period by Allie Bochicchio, both of whom are multitalented and exemplars of ever-cheerful competence, thoroughness, and helpfulness. Without the organizational skills of these two in the Garland office, this text would have emerged as an incoherent jumble.

The truly Herculean task of procuring permissions for publication of the myriad figures fell on the shoulders of Becky Hainz-Baxter. This remains a daunting task, even in this age of Internet and email. Without her help, it would have been impossible to share with the reader many of the images that have created the field of modern cancer research.

The layout is a tribute to the talents of Emma Jeffcock, once again an exemplar of competence, who has an unerring instinct for how to make images and the pages that hold them accessible and welcoming to the reader; she also provided much-valued editorial help that resulted in many improvements of the prose.

The electronic media associated with this book are the work of Michael Morales, whose ability to organize clear and effective visual presentations are indicated by the electronic files that are carried in the accompanying DVD-ROM. He and his editorial assistant, Lamia Harik, are recognized and thanked for their dedication to detail, thoroughness, and their great talent in providing accessible images that inform the reader and complement the written text.

Additional, highly valuable input into the organization and design were provided by Adam Sendroff, Alain Mentha, and Lucy Brodie.

Together, the Garland team, as cited above, represents a unique collection of gifted people whose respective talents are truly peerless and, to say so a second time, individuals who are unfailingly gracious and helpful. Other textbook authors should be as fortunate as I have been in receiving the support that I have enjoyed in the preparation of this second edition!

Contents

Chapter 1:	The Biology and Genetics of Cells and Organisms	1
Chapter 2:	The Nature of Cancer	31
Chapter 3:	Tumor Viruses	71
Chapter 4:	Cellular Oncogenes	103
Chapter 5:	Growth Factors, Receptors, and Cancer	131
Chapter 6:	Cytoplasmic Signaling Circuitry Programs Many of the Traits of Cancer	175
Chapter 7:	Tumor Suppressor Genes	231
Chapter 8:	pRb and Control of the Cell Cycle Clock	275
Chapter 9:	p53 and Apoptosis: Master Guardian and Executioner	331
Chapter 10:	Eternal Life: Cell Immortalization and Tumorigenesis	391
Chapter 11:	Multi-Step Tumorigenesis	439
Chapter 12:	Maintenance of Genomic Integrity and the Development of Cancer	511
Chapter 13:	Dialogue Replaces Monologue: Heterotypic Interactions and the Biology of Angiogenesis	577
Chapter 14:	Moving Out: Invasion and Metastasis	641
Chapter 15:	Crowd Control: Tumor Immunology and Immunotherapy	723
Chapter 16:	The Rational Treatment of Cancer	797
Abbreviations		A:1
Glossary		G:1
Index		I:1

List of Key Techniques

- Apoptotic cells: Various detection techniques (Figure 9.19)
- Apoptotic cells: Detection by the TUNEL assay (Supplementary Sidebar 9.2 )
- Chromatin immunoprecipitation (Supplementary Sidebar 8.3 )
- Circulating tumor cells: Detection using microfluidic devices (Supplementary Sidebar 14.3 )
- Comparative genomic hybridization (CGH) (Supplementary Sidebar 11.4 )
- DNA sequence polymorphisms: Detection by polymerase chain reaction (Supplementary Sidebar 7.3 )
- Embryonic stem cells: Derivation of pluripotent mouse cell lines (Supplementary Sidebar 8.1 )
- Fluorescence-activated cell sorting (FACS) (Supplementary Sidebar 11.1 )
- Gene cloning strategies (Supplementary Sidebar 1.5 )
- Gene cloning: Isolation of genes encoding melanoma antigens (Supplementary Sidebar 15.11 )
- Gene cloning: Isolation of transfected human oncogenes (Figure 4.7)
- Gene knock-in and knock-out: Homologous recombination with mouse germ-line genes (Supplementary Sidebar 7.7 )
- Histopathological staining techniques (Supplementary Sidebar 2.1 )
- Knocking down gene expression with shRNAs and siRNAs (Supplementary Sidebar 1.4 )
- Laser-capture microdissection (Supplementary Sidebar 13.5 )
- Mapping of DNA methylation sites: Use of sequence-specific polymerase chain reaction (Supplementary Sidebar 7.4 )
- Mapping of an oncogene-activating mutation (Figure 4.8)
- Mapping of tumor suppressor genes via restriction fragment length polymorphisms (Figure 7.13)
- Monoclonal antibodies (Supplementary Sidebar 11.1 )
- Mutagenicity measurement: The Ames test (Figure 2.27)
- Probe construction: The *src*-specific DNA probe (Figure 3.20)
- Reproductive cloning (Supplementary Sidebar 1.2 )
- Retroviral vector construction (Supplementary Sidebar 3.3 )
- Screening for mutant oncoproteins (Figure 16.25)
- Skin carcinoma induction in mice (Figure 11.30)
- Southern and Northern blotting (Supplementary Sidebar 4.3 )
- Telomerase activity measurements: The TRAP assay (Supplementary Sidebar 10.1 )
- Transfection of DNA (Figure 4.1)
- Transgenic mice: Creating tumor-prone strains (Figure 9.23A)

 Can be found on the DVD-ROM accompanying the book.


Detailed Contents

Chapter 1: The Biology and Genetics of Cells and Organisms	1		
1.1 Mendel establishes the basic rules of genetics	2		
1.2 Mendelian genetics helps to explain Darwinian evolution	4		
1.3 Mendelian genetics governs how both genes and chromosomes behave	7		
1.4 Chromosomes are altered in most types of cancer cells	10		
1.5 Mutations causing cancer occur in both the germ line and the soma	11		
1.6 Genotype embodied in DNA sequences creates phenotype through proteins	14		
1.7 Gene expression patterns also control phenotype	19		
1.8 Histone modification and transcription factors control gene expression	21		
1.9 Heritable gene expression is controlled through additional mechanisms	24		
1.10 Unconventional RNA molecules also affect the expression of genes	25		
1.11 Metazoa are formed from components conserved over vast evolutionary time periods	27		
1.12 Gene cloning techniques revolutionized the study of normal and malignant cells	28		
Additional reading	29		
Chapter 2: The Nature of Cancer	31		
2.1 Tumors arise from normal tissues	32		
2.2 Tumors arise from many specialized cell types throughout the body	34		
2.3 Some types of tumors do not fit into the major classifications	40		
2.4 Cancers seem to develop progressively	45		
2.5 Tumors are monoclonal growths	50		
2.6 Cancer cells exhibit an altered energy metabolism	53		
2.7 Cancers occur with vastly different frequencies in different human populations	55		
2.8 The risks of cancers often seem to be increased by assignable influences including lifestyle	58		
2.9 Specific chemical agents can induce cancer	59		
2.10 Both physical and chemical carcinogens act as mutagens	60		
2.11 Mutagens may be responsible for some human cancers	64		
2.12 Synopsis and prospects	66		
Key concepts	68		
Thought questions	69		
Additional reading	69		
Chapter 3: Tumor Viruses	71		
3.1 Peyton Rous discovers a chicken sarcoma virus	72		
3.2 Rous sarcoma virus is discovered to transform infected cells in culture	75		
3.3 The continued presence of RSV is needed to maintain transformation	77		
3.4 Viruses containing DNA molecules are also able to induce cancer	79		
3.5 Tumor viruses induce multiple changes in cell phenotype including acquisition of tumorigenicity	82		
3.6 Tumor virus genomes persist in virus-transformed cells by becoming part of host-cell DNA	83		
3.7 Retroviral genomes become integrated into the chromosomes of infected cells	87		
3.8 A version of the src gene carried by RSV is also present in uninfected cells	89		
3.9 RSV exploits a kidnapped cellular gene to transform cells	91		
3.10 The vertebrate genome carries a large group of proto-oncogenes	93		
3.11 Slowly transforming retroviruses activate proto-oncogenes by inserting their genomes adjacent to these cellular genes	94		
3.12 Some retroviruses naturally carry oncogenes	97		
3.13 Synopsis and prospects	99		
Key concepts	101		
Thought questions	102		
Additional reading	102		
Chapter 4: Cellular Oncogenes	103		
4.1 Can cancers be triggered by the activation of endogenous retroviruses?	104		
4.2 Transfection of DNA provides a strategy for detecting nonviral oncogenes	105		
4.3 Oncogenes discovered in human tumor cell lines are related to those carried by transforming retroviruses	108		
4.4 Proto-oncogenes can be activated by genetic changes affecting either protein expression or structure	113		
4.5 Variations on a theme: the <i>myc</i> oncogene can arise via at least three additional distinct mechanisms	117		
4.6 A diverse array of structural changes in proteins can also lead to oncogene activation	124		
4.7 Synopsis and prospects	127		
Key concepts	128		
Thought questions	130		
Additional reading	130		
Chapter 5: Growth Factors, Receptors, and Cancer	131		
5.1 Normal metazoan cells control each other's lives	133		
5.2 The Src protein functions as a tyrosine kinase	135		
5.3 The EGF receptor functions as a tyrosine kinase	138		
5.4 An altered growth factor receptor can function as an oncoprotein	141		
5.5 A growth factor gene can become an oncogene: the case of <i>sis</i>	144		
5.6 Transphosphorylation underlies the operations of receptor tyrosine kinases	146		
5.7 Yet other types of receptors enable mammalian cells to communicate with their environment	153		
5.8 Nuclear receptors sense the presence of low-molecular-weight lipophilic ligands	159		
5.9 Integrin receptors sense association between the cell and the extracellular matrix	161		

5.10	The Ras protein, an apparent component of the downstream signaling cascade, functions as a G protein	165	7.11	Apc facilitates egress of cells from colonic crypts	259
5.11	Synopsis and prospects	169	7.12	Von Hippel–Lindau disease: pVHL modulates the hypoxic response	265
	Key concepts	172	7.13	Synopsis and prospects	268
	Thought questions	174		Key concepts	272
	Additional reading	174		Thought questions	273
				Additional reading	273
Chapter 6: Cytoplasmic Signaling Circuitry Programs Many of the Traits of Cancer			Chapter 8: pRb and Control of the Cell Cycle Clock		
6.1	A signaling pathway reaches from the cell surface into the nucleus	177	8.1	Cell growth and division is coordinated by a complex array of regulators	276
6.2	The Ras protein stands in the middle of a complex signaling cascade	180	8.2	Cells make decisions about growth and quiescence during a specific period in the G ₁ phase	281
6.3	Tyrosine phosphorylation controls the location and thereby the actions of many cytoplasmic signaling proteins	182	8.3	Cyclins and cyclin-dependent kinases constitute the core components of the cell cycle clock	283
6.4	SH2 and SH3 groups explain how growth factor receptors activate Ras and acquire signaling specificity	188	8.4	Cyclin–CDK complexes are also regulated by CDK inhibitors	288
6.5	Ras-regulated signaling pathways: A cascade of kinases forms one of three important signaling pathways downstream of Ras	189	8.5	Viral oncoproteins reveal how pRb blocks advance through the cell cycle	294
6.6	Ras-regulated signaling pathways: a second downstream pathway controls inositol lipids and the Akt/PKB kinase	193	8.6	pRb is deployed by the cell cycle clock to serve as a guardian of the restriction-point gate	298
6.7	Ras-regulated signaling pathways: a third downstream pathway acts through Ral, a distant cousin of Ras	201	8.7	E2F transcription factors enable pRb to implement growth-versus-quiescence decisions	299
6.8	The Jak–STAT pathway allows signals to be transmitted from the plasma membrane directly to the nucleus	202	8.8	A variety of mitogenic signaling pathways control the phosphorylation state of pRb	304
6.9	Cell adhesion receptors emit signals that converge with those released by growth factor receptors	204	8.9	The Myc protein governs decisions to proliferate or differentiate	306
6.10	The Wnt– β -catenin pathway contributes to cell proliferation	206	8.10	TGF- β prevents phosphorylation of pRb and thereby blocks cell cycle progression	311
6.11	G-protein-coupled receptors can also drive normal and neoplastic proliferation	209	8.11	pRb function and the controls of differentiation are closely linked	314
6.12	Four additional “dual-address” signaling pathways contribute in various ways to normal and neoplastic proliferation	212	8.12	Control of pRb function is perturbed in most if not all human cancers	318
6.13	Well-designed signaling circuits require both negative and positive feedback controls	216	8.13	Synopsis and prospects	323
6.14	Synopsis and prospects	217		Key concepts	327
	Key concepts	227		Thought questions	328
	Thought questions	228		Additional reading	329
	Additional reading	228	Chapter 9: p53 and Apoptosis: Master Guardian and Executioner		
Chapter 7: Tumor Suppressor Genes			331		
7.1	Cell fusion experiments indicate that the cancer phenotype is recessive	232	9.1	Papovaviruses lead to the discovery of p53	332
7.2	The recessive nature of the cancer cell phenotype requires a genetic explanation	234	9.2	p53 is discovered to be a tumor suppressor gene	334
7.3	The retinoblastoma tumor provides a solution to the genetic puzzle of tumor suppressor genes	235	9.3	Mutant versions of p53 interfere with normal p53 function	335
7.4	Incipient cancer cells invent ways to eliminate wild-type copies of tumor suppressor genes	238	9.4	p53 protein molecules usually have short lifetimes	338
7.5	The <i>Rb</i> gene often undergoes loss of heterozygosity in tumors	241	9.5	A variety of signals cause p53 induction	339
7.6	Loss-of-heterozygosity events can be used to find tumor suppressor genes	243	9.6	DNA damage and deregulated growth signals cause p53 stabilization	341
7.7	Many familial cancers can be explained by inheritance of mutant tumor suppressor genes	248	9.7	Mdm2 destroys its own creator	342
7.8	Promoter methylation represents an important mechanism for inactivating tumor suppressor genes	249	9.8	ARF and p53-mediated apoptosis protect against cancer by monitoring intracellular signaling	348
7.9	Tumor suppressor genes and proteins function in diverse ways	254	9.9	p53 functions as a transcription factor that halts cell cycle advance in response to DNA damage and attempts to aid in the repair process	352
7.10	The NF1 protein acts as a negative regulator of Ras signaling	255	9.10	p53 often ushers in the apoptotic death program	355
			9.11	p53 inactivation provides advantage to incipient cancer cells at a number of steps in tumor progression	359
			9.12	Inherited mutant alleles affecting the p53 pathway predispose one to a variety of tumors	360
			9.13	Apoptosis is a complex program that often depends on mitochondria	361
			9.14	Both intrinsic and extrinsic apoptotic programs can lead to cell death	371
			9.15	Cancer cells invent numerous ways to inactivate some or all of the apoptotic machinery	376
			9.16	Necrosis and autophagy: two additional forks in the road of tumor progression	379

9.17 Synopsis and prospects	381	11.15 Chronic inflammation often serves to promote tumor progression in mice and humans	486
Key concepts	387	11.16 Inflammation-dependent tumor promotion operates through defined signaling pathways	490
Thought questions	388	11.17 Tumor promotion is likely to be a critical determinant of the rate of tumor progression in many human tissues	498
Additional reading	389	11.18 Synopsis and prospects	501
Chapter 10: Eternal Life: Cell Immortalization and Tumorigenesis	391	Key concepts	506
10.1 Normal cell populations register the number of cell generations separating them from their ancestors in the early embryo	392	Thought questions	507
10.2 Cancer cells need to become immortal in order to form tumors	394	Additional reading	508
10.3 Cell-physiologic stresses impose a limitation on replication	398	Chapter 12: Maintenance of Genomic Integrity and the Development of Cancer	511
10.4 The proliferation of cultured cells is also limited by the telomeres of their chromosomes	404	12.1 Tissues are organized to minimize the progressive accumulation of mutations	512
10.5 Telomeres are complex molecular structures that are not easily replicated	409	12.2 Stem cells may or may not be targets of the mutagenesis that leads to cancer	515
10.6 Incipient cancer cells can escape crisis by expressing telomerase	412	12.3 Apoptosis, drug pumps, and DNA replication mechanisms offer tissues a way to minimize the accumulation of mutant stem cells	517
10.7 Telomerase plays a key role in the proliferation of human cancer cells	417	12.4 Cell genomes are threatened by errors made during DNA replication	519
10.8 Some immortalized cells can maintain telomeres without telomerase	419	12.5 Cell genomes are under constant attack from endogenous biochemical processes	523
10.9 Telomeres play different roles in the cells of laboratory mice and in human cells	423	12.6 Cell genomes are under occasional attack from exogenous mutagens and their metabolites	527
10.10 Telomerase-negative mice show both decreased and increased cancer susceptibility	425	12.7 Cells deploy a variety of defenses to protect DNA molecules from attack by mutagens	535
10.11 The mechanisms underlying cancer pathogenesis in telomerase-negative mice may also operate during the development of human tumors	429	12.8 Repair enzymes fix DNA that has been altered by mutagens	538
10.12 Synopsis and prospects	433	12.9 Inherited defects in nucleotide-excision repair, base-excision repair, and mismatch repair lead to specific cancer susceptibility syndromes	544
Key concepts	436	12.10 A variety of other DNA repair defects confer increased cancer susceptibility through poorly understood mechanisms	549
Thought questions	437	12.11 The karyotype of cancer cells is often changed through alterations in chromosome structure	555
Additional reading	437	12.12 The karyotype of cancer cells is often changed through alterations in chromosome number	558
Chapter 11: Multi-Step Tumorigenesis	439	12.13 Synopsis and prospects	564
11.1 Most human cancers develop over many decades of time	440	Key concepts	572
11.2 Histopathology provides evidence of multi-step tumor formation	442	Thought questions	573
11.3 Cells accumulate genetic and epigenetic alterations as tumor progression proceeds	449	Additional reading	574
11.4 Multi-step tumor progression helps to explain familial polyposis and field cancerization	453	Chapter 13 Dialogue Replaces Monologue: Heterotypic Interactions and the Biology of Angiogenesis	577
11.5 Cancer development seems to follow the rules of Darwinian evolution	455	13.1 Normal and neoplastic epithelial tissues are formed from interdependent cell types	579
11.6 Tumor stem cells further complicate the Darwinian model of clonal succession and tumor progression	458	13.2 The cells forming cancer cell lines develop without heterotypic interactions and deviate from the behavior of cells within human tumors	585
11.7 A linear path of clonal succession oversimplifies the reality of cancer: intra-tumor heterogeneity	463	13.3 Tumors resemble wounded tissues that do not heal	587
11.8 The Darwinian model of tumor development is difficult to validate experimentally	467	13.4 Experiments directly demonstrate that stromal cells are active contributors to tumorigenesis	600
11.9 Multiple lines of evidence reveal that normal cells are resistant to transformation by a single mutated gene	468	13.5 Macrophages and myeloid cells play important roles in activating the tumor-associated stroma	604
11.10 Transformation usually requires collaboration between two or more mutant genes	470	13.6 Endothelial cells and the vessels that they form ensure tumors adequate access to the circulation	607
11.11 Transgenic mice provide models of oncogene collaboration and multi-step cell transformation	474	13.7 Tripping the angiogenic switch is essential for tumor expansion	615
11.12 Human cells are constructed to be highly resistant to immortalization and transformation	475	13.8 The angiogenic switch initiates a highly complex process	619
11.13 Nonmutagenic agents, including those favoring cell proliferation, make important contributions to tumorigenesis	480	13.9 Angiogenesis is normally suppressed by physiologic inhibitors	622
11.14 Toxic and mitogenic agents can act as human tumor promoters	484	13.10 Anti-angiogenesis therapies can be employed to treat cancer	626

13.11	Synopsis and prospects	634	15.13	Cancer cells can evade immune detection by suppressing cell-surface display of tumor antigens	761
	Key concepts	638	15.14	Cancer cells protect themselves from destruction by NK cells and macrophages	765
	Thought questions	639	15.15	Tumor cells launch counterattacks on immunocytes	769
	Additional reading	639	15.16	Cancer cells become intrinsically resistant to various forms of killing used by the immune system	773
	Chapter 14: Moving Out: Invasion and Metastasis	641	15.17	Cancer cells attract regulatory T cells to fend off attacks by other lymphocytes	774
14.1	Travel of cancer cells from a primary tumor to a site of potential metastasis depends on a series of complex biological steps	643	15.18	Passive immunization with monoclonal antibodies can be used to kill breast cancer cells	778
14.2	Colonization represents the most complex and challenging step of the invasion–metastasis cascade	652	15.19	Passive immunization with antibody can also be used to treat B-cell tumors	781
14.3	The epithelial–mesenchymal transition and associated loss of E-cadherin expression enable carcinoma cells to become invasive	657	15.20	Transfer of foreign immunocytes can lead to cures of certain hematopoietic malignancies	785
14.4	Epithelial–mesenchymal transitions are often induced by contextual signals	662	15.21	Patients' immune systems can be mobilized to attack their tumors	786
14.5	Stromal cells contribute to the induction of invasiveness	669	15.22	Synopsis and prospects	791
14.6	EMTs are programmed by transcription factors that orchestrate key steps of embryogenesis	672		Key concepts	793
14.7	EMT-inducing transcription factors also enable entrance into the stem cell state	677		Thought questions	795
14.8	EMT-inducing TFs help drive malignant progression	680		Additional reading	795
14.9	Extracellular proteases play key roles in invasiveness	685		Chapter 16: The Rational Treatment of Cancer	797
14.10	Small Ras-like GTPases control cellular processes such as adhesion, cell shape, and cell motility	689	16.1	The development and clinical use of effective therapies will depend on accurate diagnosis of disease	800
14.11	Metastasizing cells can use lymphatic vessels to disperse from the primary tumor	695	16.2	Surgery, radiotherapy, and chemotherapy are the major pillars on which current cancer therapies rest	806
14.12	A variety of factors govern the organ sites in which disseminated cancer cells form metastases	699	16.3	Differentiation, apoptosis, and cell cycle checkpoints can be exploited to kill cancer cells	813
14.13	Metastasis to bone requires the subversion of osteoblasts and osteoclasts	703	16.4	Functional considerations dictate that only a subset of the defective proteins in cancer cells are attractive targets for drug development	815
14.14	Metastasis suppressor genes contribute to regulating the metastatic phenotype	709	16.5	The biochemistry of proteins also determines whether they are attractive targets for intervention	818
14.15	Occult micrometastases threaten the long-term survival of cancer patients	711	16.6	Pharmaceutical chemists can generate and explore the biochemical properties of a wide array of potential drugs	822
14.16	Synopsis and prospects	713	16.7	Drug candidates must be tested on cell models as an initial measurement of their utility in whole organisms	825
	Key concepts	719	16.8	Studies of a drug's action in laboratory animals are an essential part of pre-clinical testing	826
	Thought questions	720	16.9	Promising candidate drugs are subjected to rigorous clinical tests in Phase I trials in humans	829
	Additional reading	721	16.10	Phase II and III trials provide credible indications of clinical efficacy	831
	Chapter 15: Crowd Control: Tumor Immunology and Immunotherapy	723	16.11	Tumors often develop resistance to initially effective therapy	833
15.1	The immune system functions to destroy foreign invaders and abnormal cells in the body's tissues	724	16.12	Gleevec paved the way for the development of many other highly targeted compounds	834
15.2	The adaptive immune response leads to antibody production	726	16.13	EGF receptor antagonists may be useful for treating a wide variety of tumor types	844
15.3	Another adaptive immune response leads to the formation of cytotoxic cells	729	16.14	Proteasome inhibitors yield unexpected therapeutic benefit	850
15.4	The innate immune response does not require prior sensitization	736	16.15	A sheep teratogen may be useful as a highly potent anti-cancer drug	855
15.5	The need to distinguish self from non-self results in immune tolerance	736	16.16	mTOR, a master regulator of cell physiology, represents an attractive target for anti-cancer therapy	861
15.6	Regulatory T cells are able to suppress major components of the adaptive immune response	737	16.17	B-Raf discoveries have led to inroads into the melanoma problem	864
15.7	The immunosurveillance theory is born and then suffers major setbacks	739	16.18	Synopsis and prospects: challenges and opportunities on the road ahead	866
15.8	Use of genetically altered mice leads to a resurrection of the immunosurveillance theory	742		Key concepts	874
15.9	The human immune system plays a critical role in warding off various types of human cancer	745		Thought questions	875
15.10	Subtle differences between normal and neoplastic tissues may allow the immune system to distinguish between them	751		Additional reading	875
15.11	Tumor transplantation antigens often provoke potent immune responses	756			
15.12	Tumor-associated transplantation antigens may also evoke anti-tumor immunity	758			



Chapter 1

The Biology and Genetics of Cells and Organisms

Protoplasm, simple or nucleated, is the formal basis of all life... Thus it becomes clear that all living powers are cognate, and that all living forms are fundamentally of one character. The researches of the chemist have revealed a no less striking uniformity of material composition in living matter.

Thomas Henry Huxley, evolutionary biologist, 1868

Anything found to be true of *E. coli* must also be true of elephants.

Jacques Monod, pioneer molecular biologist, 1954

The biological revolution of the twentieth century totally reshaped all fields of biomedical study, cancer research being only one of them. The fruits of this revolution were revelations of both the outlines and the minute details of genetics and heredity, of how cells grow and divide, how they assemble to form tissues, and how the tissues develop under the control of specific genes. Everything that follows in this text draws directly or indirectly on this new knowledge.

This revolution, which began in mid-century and was triggered by Watson and Crick's discovery of the DNA double helix, continues to this day. Indeed, we are still too close to this breakthrough to properly understand its true importance and its long-term ramifications. The discipline of molecular biology, which grew from this discovery, delivered solutions to the most profound problem of twentieth-century biology—how does the genetic constitution of a cell or organism determine its appearance and function?


Without this molecular foundation, modern cancer research, like many other biological disciplines, would have remained a descriptive science that cataloged diverse biological phenomena without being able to explain the mechanics of how they occur.

Movies in this chapter

- 1.1 Replication I
- 1.2 Replication II
- 1.3 Translation I
- 1.4 Transcription

Figure 1.1 Darwin and Mendel

(A) Charles Darwin's 1859 publication of *On the Origin of Species by Means of Natural Selection* exerted a profound effect on thinking about the origin of life, the evolution of organismic complexity, and the relatedness of species. (B) Darwin's theory of evolution lacked a genetic rationale until the work of Gregor Mendel. The synthesis of Darwinian evolution and Mendelian genetics is the foundation for much of modern biological thinking. (A, from the Grace K. Babson Collection, the Henry E. Huntington Library, San Marino, California. Reproduced by permission of The Huntington Library, San Marino, California. B, courtesy of the Mendelianum Museum Moraviae, Brno, Czech Republic.)



(A)



(B)

Today, our understanding of how cancers arise is being continually enriched by discoveries in diverse fields of biological research, most of which draw on the sciences of molecular biology and genetics. Perhaps unexpectedly, many of our insights into the origins of malignant disease are not coming from the laboratory benches of cancer researchers. Instead, the study of diverse organisms, ranging from yeast to worms to flies, provides us with much of the intellectual capital that fuels the forward thrust of the rapidly moving field of cancer research.

Those who fired up this biological revolution stood on the shoulders of nineteenth-century giants, specifically, Darwin and Mendel (Figure 1.1). Without the concepts established by these two, which influence all aspects of modern biological thinking, molecular biology and contemporary cancer research would be inconceivable. So, throughout this chapter, we frequently make reference to evolutionary processes as proposed by Charles Darwin and genetic systems as conceived by Gregor Mendel.

1.1 Mendel establishes the basic rules of genetics

Many of the basic rules of genetics that govern how genes are passed from one complex organism to the next were discovered in the 1860s by Gregor Mendel and have come to us basically unchanged. Mendel's work, which tracked the breeding of pea plants, was soon forgotten, only to be rediscovered independently by three researchers in 1900. During the decade that followed, it became clear that these rules—we now call them Mendelian genetics—apply to virtually all sexual organisms, including **metazoa** (multicellular animals), as well as **metaphyta** (multicellular plants).

Mendel's most fundamental insight came from his realization that genetic information is passed in particulate form from an organism to its offspring. This implied that the entire repertoire of an organism's genetic information—its genome, in today's terminology—is organized as a collection of discrete, separable information packets, now called genes. Only in recent years have we begun to know with any precision how many distinct genes are present in the genomes of mammals; many current analyses of the human genome—the best studied of these—place the number in the range of 21,000, somewhat more than the 14,500 genes identified in the genome of the fruit fly, *Drosophila melanogaster*.

Mendel's work also implied that the constitution of an organism, including its physical and chemical makeup, could be divided into a series of discrete, separable entities. Mendel went further by showing that distinct anatomical parts are controlled by distinct genes. He found that the heritable material controlling the smoothness of peas behaved independently of the material governing plant height or flower color. In















	Seed shape	Seed color	Flower color	Flower position	Pod shape	Pod color	Plant height
One form of trait (dominant)	round 	yellow 	violet-red 	axial 	inflated 	green 	tall 
A second form of trait (recessive)	wrinkled 	green 	white 	terminal 	pinched 	yellow 	short 

Figure 1.2 A particulate theory of inheritance One of Gregor Mendel's principal insights was that the genetic content of an organism consists of discrete parcels of information, each responsible for a distinct observable trait. Shown are the seven pea-plant traits that Mendel studied through breeding experiments. Each trait had two observable (phenotypic) manifestations, which we now know to be specified by the alternative versions of genes that we call alleles. When the two alternative alleles coexisted within a single plant, the "dominant" trait (*above*) was always observed while the "recessive" trait (*below*) was never observed. (Courtesy of J. Postlethwait and J. Hopson.)

effect, each observable trait of an individual might be traceable to a separate gene that served as its blueprint. Thus, Mendel's research implied that the genetic constitution of an organism (its **genotype**) could be divided into hundreds, perhaps thousands of discrete information packets; in parallel, its observable, outward appearance (its **phenotype**) could be subdivided into a large number of discrete physical or chemical traits (Figure 1.2).

Mendel's thinking launched a century-long research project among geneticists, who applied his principles to studying thousands of traits in a variety of experimental animals, including flies (*Drosophila melanogaster*), worms (*Caenorhabditis elegans*), and mice (*Mus musculus*). In the mid-twentieth century, geneticists also began to apply Mendelian principles to study the genetic behavior of single-celled organisms, such as the bacterium *Escherichia coli* and baker's yeast, *Saccharomyces cerevisiae*. The principle of genotype governing phenotype was directly transferable to these simpler organisms and their genetic systems.

While Mendelian genetics represents the foundation of contemporary genetics, it has been adapted and extended in myriad ways since its embodiments of 1865 and 1900. For example, the fact that single-celled organisms often reproduce asexually, that is, without mating, created the need for adaptations of Mendel's original rules. Moreover, the notion that each attribute of an organism could be traced to instructions carried in a single gene was realized to be simplistic. The great majority of observable traits of an organism are traceable to the cooperative interactions of a number of genes. Conversely, almost all the genes carried in the genome of a complex organism play roles in the development and maintenance of multiple organs, tissues, and physiologic processes.

Mendelian genetics revealed for the first time that genetic information is carried redundantly in the genomes of complex plants and animals. Mendel deduced that there were two copies of a gene for flower color and two for pea shape. Today we know that this twofold redundancy applies to the entire genome with the exception of the genes carried in the sex chromosomes. Hence, the genomes of higher organisms are termed **diploid**.

Mendel's observations also indicated that the two copies of a gene could convey different, possibly conflicting information. Thus, one gene copy might specify rough-surfaced and the other smooth-surfaced peas. In the twentieth century, these different versions of a gene came to be called **alleles**. An organism may carry two identical alleles of a gene, in which case, with respect to this gene, it is said to be **homozygous**. Conversely, the presence of two different alleles of a gene in an organism's genome renders this organism **heterozygous** with respect to this gene.

Because the two alleles of a gene may carry conflicting instructions, our views of how genotype determines phenotype become more complicated. Mendel found that in many instances, the voice of one allele may dominate over that of the other in deciding the ultimate appearance of a trait. For example, a pea genome may be heterozygous for the gene that determines the shape of peas, carrying one round and one wrinkled allele. However, the pea plant carrying this pair of alleles will invariably produce round peas. This indicates that the round allele is **dominant**, and that it will invariably overrule its **recessive** counterpart allele (wrinkled) in determining phenotype (see Figure 1.2). (Strictly speaking, using proper genetic parlance, we would say that the phenotype encoded by one allele of a gene is dominant with respect to the phenotype encoded by another allele, the latter phenotype being recessive.)

In fact, classifying alleles as being either dominant or recessive oversimplifies biological realities. The alleles of some genes may be **co-dominant**, in that an expressed phenotype may represent a blend of the actions of the two alleles. Equally common are examples of **incomplete penetrance**, in which case a dominant allele may be present but its phenotype is not manifested because of the actions of other genes within the organism's genome. Therefore, the dominance of an allele is gauged by its interactions with other allelic versions of its gene, rather than its ability to dictate phenotype.

With such distinctions in mind, we note that the development of tumors also provides us with examples of dominance and recessiveness. For instance, one class of alleles that predispose cells to develop cancer encode defective versions of enzymes involved in DNA repair and thus in the maintenance of genomic integrity (discussed again in Chapter 12). These defective alleles are relatively rare in the general population and function recessively. Consequently, their presence in the genomes of many **heterozygotes** (of a wild-type/mutant genotype) is not apparent. However, two heterozygotes carrying recessive defective alleles of the same DNA repair gene may mate. One-fourth of the offspring of such mating pairs, on average, will inherit two defective alleles, exhibit a specific DNA repair defect in their cells, and develop certain types of cancer at greatly increased rates (Figure 1.3).

1.2 Mendelian genetics helps to explain Darwinian evolution

In the early twentieth century, it was not apparent how the distinct allelic versions of a gene arise. At first, this variability in information content seemed to have been present in the collective gene pool of a species from its earliest evolutionary beginnings. This perception changed only later, beginning in the 1920s and 1930s, when it became apparent that genetic information is corruptible; the information content in genetic texts, like that in all texts, can be altered. **Mutations** were found to be responsible for changing the information content of a gene, thereby converting one allele into another or creating a new allele from one previously widespread within a species. An allele that is present in the great majority of individuals within a species is usually termed **wild type**, the term implying that such an allele, being naturally present in large numbers of apparently healthy organisms, is compatible with normal structure and function.




Figure 1.3 Discrepancy between genotype and phenotype The phenotype of an individual often does not indicate genotype. For example, individuals who are phenotypically normal for a trait may nevertheless, at the level of genotype, carry one wild-type (normal) and one mutant (defective) allele of the gene that specifies this trait; this mutant allele will be recessive to the wild-type allele, the latter being dominant. Such individuals are heterozygotes with respect to this gene. In the example shown here, two individuals mate, both of whom are phenotypically normal but heterozygous for a gene specifying a DNA repair function. On average, of their four children, three will be phenotypically normal and their cells will exhibit normal DNA repair function: one of these children will receive two wild-type alleles (be a homozygote) and two will be heterozygotes like their parents. A fourth child, however, will receive two mutant alleles (i.e., be a homozygote) and will be phenotypically mutant, in that this child's cells will lack the DNA repair function specified by this gene. Individuals whose cells lack proper DNA repair function are often cancer-prone, as described in Chapter 12.

Mutations alter genomes continually throughout the evolutionary life span of a species, which usually extends over millions of years. They strike the genome and its constituent genes randomly. Mutations provide a species with a method for continually tinkering with its genome, for trying out new versions of genes that offer the prospect of novel, possibly improved phenotypes. The result of the continuing mutations on the genome is a progressive increase during the evolutionary history of a species in the genetic diversity of its members. Thus, the collection of alleles present in the genomes of all members of a species—the **gene pool** of this species—becomes progressively more heterogeneous as the species grows older.

This means that older species carry more distinct alleles in their genomes than younger ones. Humans, belonging to a relatively young species (<150,000 years old), have one-third as many alleles and genetic diversity as chimpanzees, allowing us to infer that they have been around as a species three times longer than we have.

The continuing diversification of alleles in a species' genome, occurring over millions of years, is countered to some extent by the forces of natural selection that Charles Darwin first described. Some alleles of a gene may confer more advantageous phenotypes than others, so individuals carrying these alleles have a greater probability of leaving numerous descendants than do those members of the same species that lack them. Consequently, natural selection results in a continual discarding of many of the alleles that have been generated by random mutations. In the long run, all things being equal, disadvantageous alleles are lost from the pool of alleles carried by the members of a species, advantageous alleles increase in number, and the overall fitness of the species improves incrementally.

Now, more than a century after Mendel was rediscovered and Mendelian genetics revived, we have come to realize that the great bulk of the genetic information in our own genome—indeed, in the genomes of all mammals—does not seem to specify phenotype and is often not associated with specific genes. Reflecting the discovery in 1944 that genetic information is encoded in DNA molecules, these “noncoding” stretches in the genome are often called **junk DNA** (Figure 1.4). Only about 1.5% of a mammal's genomic DNA carries sequence information that encodes the structures of proteins. Recent sequence comparisons of human, mouse, and dog genomes suggest that another ~2% encodes important information regulating gene expression and mediating other, still-poorly understood functions.

Because mutations act randomly on a genome, altering true genes and junk DNA indiscriminately, the great majority of mutations alter genetic information—nucleotide sequences in the DNA—that have no effect on cellular or organismic phenotype. These mutations remain silent phenotypically and are said, from the point of view of natural selection, to be **neutral mutations**, being neither advantageous nor




Figure 1.4 Biologically important sequences in the human genome The human genome can be characterized as a collection of relatively small islands of biologically important sequences (~3.5% of the total genome; red) floating amid a sea of “junk” DNA (yellow). The proportion of sequences carrying biological information has been greatly exaggerated for the sake of illustration. (With the passage of time, genes that appear to play important roles in cell and organismic physiology and specify certain noncoding RNA species have been localized to these intergenic regions; hence the blanket classification of all genomic sequences localized between a human cell’s ~21,000 protein-coding genes as useless junk is simplistic.)

disadvantageous (Figure 1.5). Since the alleles created by these mutations are silent, their existence could not be discerned by early geneticists whose work depended on gauging phenotypes. However, with the advent of DNA sequencing techniques, it became apparent that hundreds of thousands, even a million functionally silent






Figure 1.5 Neutral mutations and evolution (A) The coding sequences (red) of most genes were optimized in the distant evolutionary past. Hence, many mutations affecting amino acid sequence and thus protein structure (left) create alleles that compromise the organism’s ability to survive. For this reason, these mutant alleles are likely to be eliminated from the species’ gene pool. In contrast, mutations striking “junk” DNA (yellow) have no effect on phenotype and are therefore often preserved in the species’ gene pool (right). This explains why, over extended periods of evolutionary time, coding DNA sequences change slowly, while

noncoding DNA sequences change far more rapidly. (B) Depicted is a physical map of a randomly chosen 0.1-megabase segment of human Chromosome 1 (from base pair 112,912,286 to base pair 113,012,285) containing four genes. Each consists of a few islands (solid rectangles) that are known or likely to specify segments of mRNA molecules (i.e., exons) and large stretches of intervening sequences (i.e., introns) that do not appear to specify biological information (see Figure 1.16). The large stretches of DNA sequence between genes have not been associated with any biological function. (B, courtesy of The Wellcome Trust Sanger Institute.)

Figure 1.6 Polymorphic diversity in the human gene pool Because the great majority of human genomic DNA does not encode biologically important information (*yellow*), it has evolved relatively rapidly and has accumulated many subtle differences in sequences—polymorphisms—that are phenotypically silent (see Figure 1.5). Such polymorphisms are transmitted like Mendelian alleles, but their presence in a genome can be ascertained only by molecular techniques such as DNA sequencing. The dots (*green*) indicate where the sequence on this chromosome differs from the sequence that is most common in the human gene pool. For example, the prevalent sequence in one stretch may be TAACTGG, while the variant sequence T~~A~~ACTGG may be carried by a minority of humans and constitute a polymorphism. The presence of a polymorphism in one chromosome but not the other represents a region of heterozygosity, even though a nearby gene (*red*) may be present in the identical allelic version on both chromosomes and therefore be in a homozygous configuration.



mutations can be found scattered throughout the genomes of organisms such as humans. The genome of each human carries its own unique array of these functionally silent genetic alterations. The term *polymorphism* was originally used to describe variations in shape and form that distinguish normal individuals within a species from each other. These days, geneticists use the term **genetic polymorphisms** to describe the inter-individual, functionally silent differences in DNA sequence that make each human genome unique (Figure 1.6).

During the course of evolution, the approximately 3.5% of the genome that does encode biological function behaves much differently from the junk DNA. Junk DNA sequences suffer mutations that have no effect on the viability of an organism. Consequently, countless mutations in the noncoding sequences of a species' genome survive in its gene pool and accumulate progressively during its evolutionary history. In contrast, mutations affecting the coding sequences usually lead to loss of function and, as a consequence, loss of organismic viability; hence, these mutations are weeded out of the gene pool by the hand of natural selection, explaining why genetic sequences that do specify biological phenotypes generally change very slowly over long evolutionary time periods (Sidebar 1.1).

1.3 Mendelian genetics governs how both genes and chromosomes behave

In the first decade of the twentieth century, Mendel's rules of genetics were found to have a striking parallel in the behavior of the chromosomes that were then being visualized under the light microscope. Both Mendel's genes and the chromosomes were found to be present in pairs. Soon it became clear that an identical set of chromosomes is present in almost all the cells of a complex organism. This chromosomal array, often termed the **karyotype**, was found to be duplicated each time a cell went through a cycle of growth and division.

The parallels between the behaviors of genes and chromosomes led to the speculation, soon validated in hundreds of different ways, that the mysterious information packets called genes were carried by the chromosomes. Each chromosome was realized to carry its own unique set of genes in a linear array. Today, we know that as many as several thousand genes may be arrayed along a mammalian chromosome. (Human Chromosome 1—the largest of the set—holds at least 3148 distinct genes.) Indeed, the length of a chromosome, as viewed under the microscope, is roughly proportional to the number of genes that it carries.


Each gene was found to be localized to a specific site along the length of a specific chromosome. This site is often termed a genetic **locus**. Much effort was expended by geneticists throughout the twentieth century to map the sites of genes—genetic loci—along the chromosomes of a species (Figure 1.8).

Sidebar 1.1 Evolutionary forces dictate that certain genes are highly conserved Many genes encode cellular traits that are essential for the continued viability of the cell. These genes, like all others in the genome, are susceptible to the ever-tinkering hand of mutation, which is continually creating new gene sequences by altering existing ones. Natural selection tests these novel sequences and determines whether they specify phenotypes that are more advantageous than the preexisting ones.

Almost invariably, the sequences in genes required for cell and therefore organismic viability were already optimized hundreds of millions of years ago. Consequently, almost all subsequently occurring changes in the sequence information of these genes would have been deleterious and would have compromised the viability of the cell and, in turn, the organism. These mutant alleles were soon lost, because the mutant organisms carrying them failed to leave descendants. This dynamic explains why the sequences of many genes have been highly conserved over vast evolutionary time periods. Stated more accurately, the structures of their encoded proteins have been highly conserved.

In fact, the great majority of the proteins that are present in our own cells and are required for cell viability were first developed during the evolution of single-cell **eukaryotes**. This is indicated by numerous observations showing that many of our proteins have clearly recognizable counterparts in single-cell eukaryotes, such as baker's yeast. Another large repertoire of highly conserved genes and proteins is traceable to the appearance of the first multicellular animals (metazoa); these genes enabled the development of distinct organs and of organismic physiology. Hence, another large group of our own genes and proteins is present in counterpart form in worms and flies (Figure 1.7).

By the time the ancestor of all mammals first appeared more than 150 million years ago, virtually all the biochemical and molecular features present in contemporary mammals had already been developed. The fact that they have changed little in the intervening time points to their optimization long before the appearance of the various mammalian orders. This explains why the embryogenesis, physiology, and biochemistry of all mammals is very similar, indeed, so similar that lessons learned through the study of laboratory mice are almost always transferable to an understanding of human biology.



The diploid genetic state that reigns in most cells throughout the body was found to be violated in the *germ cells*, sperm and egg. These cells carry only a single copy of each chromosome and gene and thus are said to be **haploid**. During the formation of germ cells in the testes and ovaries, each pair of chromosomes is separated and one of the pair (and thus associated genes) is chosen at random for incorporation into the sperm or egg. When sperm and egg combine subsequently during fertilization,





Figure 1.8 Localization of genes along chromosomes (A) The physical structure of *Drosophila* chromosomes was mapped by using the fly's salivary gland chromosomes, which exhibit banding patterns resulting from alternating light (sparse) and dark (condensed) chromosomal regions (*bottom*). Independently, genetic crosses yielded linear maps (*top*) of various genetic loci arrayed along the chromosomes. These loci were then aligned with physical banding maps, like the one shown here for the beginning of the left arm of *Drosophila* chromosome 1. (B) The availability of DNA probes that hybridize specifically to various genes now makes it possible to localize genes along a chromosome by tagging each probe with a specific fluorescent dye or combination of dyes. Shown are six genes that were localized to various sites along human Chromosome 5 by using fluorescence *in situ* hybridization (FISH) during metaphase. (There are two dots for each gene because chromosomes are present in duplicate form during metaphase of mitosis.) (A, from M. Singer and P. Berg, *Genes and Genomes*. Mill Valley, CA: University Science Books, 1991, as taken from C.B. Bridges, *J. Hered.* 26:60, 1935. B, courtesy of David C. Ward.)

the two haploid genomes fuse to yield the new diploid genome of the fertilized egg. All cells in the organism descend directly from this diploid cell and, if all goes well, inherit precise replicas of its diploid genome. In a large multicellular organism like the human, this means that a complete copy of the genome is present in almost all of the approximately 3×10^{13} cells throughout the body!

With the realization that genes reside in chromosomes, and that a complete set of chromosomes is present in almost all cell types in the body, came yet another conclusion that was rarely noted: genes create the phenotypes of an organism through their ability to act locally by influencing the behavior of its individual cells. The alternative—that a single set of genes residing at some unique anatomical site in the organism controls the entire organism's development and physiology—was now discredited.

The rule of paired, similarly appearing chromosomes was found to be violated by some of the sex chromosomes. In the cells of female placental mammals, there are two similarly appearing X chromosomes, and these behave like the **autosomes** (the nonsex chromosomes). But in males, an X chromosome is paired with a Y chromosome, which is smaller and carries a much smaller repertoire of genes. In humans, the X chromosome is thought to carry about 900 genes, compared with the 78 distinct genes on the Y chromosome, which, because of redundancy, specify only 27 distinct proteins (**Figure 1.9**).

This asymmetry in the configuration of the sex chromosomes puts males at a biological disadvantage. Many of the 900 or so genes on the X chromosome are vital to normal organismic development and function. The twofold redundancy created by the paired X chromosomes guarantees more robust biology. If a gene copy on one of the X chromosomes is defective (that is, a nonfunctional mutant allele), chances are that the second copy of the gene on the other X chromosome can continue to carry out the task of the gene, ensuring normal biological function. Males lack this genetic fail-safe system in their sex chromosomes. One of the more benign consequences of this is color blindness, which strikes males frequently and females infrequently, due to the localization on the X chromosome of the genes encoding the color-sensing proteins of the retina.

This disparity between the genders is mitigated somewhat by the mechanism of X-inactivation. Early in embryogenesis, one of the two X chromosomes is randomly